The cost-effectiveness of nivolumab monotherapy for the treatment of advanced melanoma patients in England.

Yang Meng,N. Hertel,John Ellis,Edith Morais,Helen Johnson,Zoe Philips,Neil Roskell,Andrew Walker,Dawn Lee

The cost-effectiveness of nivolumab monotherapy for the treatment of advanced melanoma patients in England.

2018

Yang Meng
N. Hertel
John Ellis
Edith Morais
Helen Johnson
Zoe Philips
Neil Roskell
Andrew Walker
Dawn Lee

Background Nivolumab was the first programmed death receptor 1 (PD-1) immune checkpoint inhibitor to demonstrate long-term survival benefit in a clinical trial setting for advanced melanoma patients.

Keywords:

Nivolumab
Physical therapy
Melanoma
Clinical trial
Cancer research
Medicine
Immune checkpoint
Oncology
advanced melanoma
health care management
Internal medicine
programmed death
survival benefit
immune checkpoint inhibitors
cost effectiveness

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations